Virbac jumps over 8%, on the back of a recommendation upgrade from 'hold' to 'buy' by Stifel, with a price target raised from 380 to 390 euros, the broker believing that the risk/reward ratio is becoming more attractive.

Although decelerating, we believe Virbac has published reassuring figures for the second half of 2024", notes Stifel, for whom "the group should continue to slightly outperform long-term growth in the animal health market".

Copyright (c) 2025 CercleFinance.com. All rights reserved.